HUMA vs. AVXL, IVVD, LXEO, TCRX, MGTX, TNYA, ALVO, PROK, AURA, and MGX
Should you be buying Humacyte stock or one of its competitors? The main competitors of Humacyte include Anavex Life Sciences (AVXL), Invivyd (IVVD), Lexeo Therapeutics (LXEO), TScan Therapeutics (TCRX), MeiraGTx (MGTX), Tenaya Therapeutics (TNYA), Alvotech (ALVO), ProKidney (PROK), Aura Biosciences (AURA), and Metagenomi (MGX). These companies are all part of the "biological products, except diagnostic" industry.
Anavex Life Sciences (NASDAQ:AVXL) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, community ranking, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.
Humacyte's return on equity of -30.32% beat Anavex Life Sciences' return on equity.
In the previous week, Anavex Life Sciences had 11 more articles in the media than Humacyte. MarketBeat recorded 13 mentions for Anavex Life Sciences and 2 mentions for Humacyte. Anavex Life Sciences' average media sentiment score of 0.31 beat Humacyte's score of 0.08 indicating that Humacyte is being referred to more favorably in the news media.
Anavex Life Sciences presently has a consensus target price of $40.00, suggesting a potential upside of 859.23%. Humacyte has a consensus target price of $8.00, suggesting a potential upside of 151.57%. Given Humacyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Anavex Life Sciences is more favorable than Humacyte.
Anavex Life Sciences received 408 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 74.08% of users gave Anavex Life Sciences an outperform vote while only 48.39% of users gave Humacyte an outperform vote.
Anavex Life Sciences has higher earnings, but lower revenue than Humacyte. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 11.6% of Anavex Life Sciences shares are held by company insiders. Comparatively, 23.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Anavex Life Sciences has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
Summary
Anavex Life Sciences beats Humacyte on 9 of the 16 factors compared between the two stocks.
Get Humacyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HUMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Humacyte Competitors List
Related Companies and Tools